Literature DB >> 20065058

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.

Tsai-Ling Lauderdale1, Yih-Ru Shiau, Jui-Fen Lai, Hua-Chien Chen, Chi-Hsin R King.   

Abstract

The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20065058      PMCID： PMC2825994          DOI： 10.1128/AAC.01197-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Antibacterial resistance worldwide: causes, challenges and responses.

Authors:  Stuart B Levy; Bonnie Marshall
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

2.  Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan.

Authors:  Jing-Jou Yan; Po-Ren Hsueh; Jang-Jih Lu; Feng-Yee Chang; Jainn-Ming Shyr; Jen-Hsien Wan; Yung-Ching Liu; Yin-Ching Chuang; Yi-Chueh Yang; Shih-Ming Tsao; Hsiu-Hung Wu; Li-Shin Wang; Tsuey-Pin Lin; Hsiu-Mei Wu; Hung-Mo Chen; Jiunn-Jong Wu
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 3.  The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  David M Livermore; Neil Woodford
Journal:  Trends Microbiol       Date:  2006-07-31       Impact factor: 17.079

4.  The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000.

Authors:  L Clifford McDonald; Tsai-Ling Lauderdale; Yih-Ru Shiau; Pei-Chen Chen; Jui-Fen Lai; Hui-Ying Wang; Monto Ho
Journal:  Int J Antimicrob Agents       Date:  2004-04       Impact factor: 5.283

5.  Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.

Authors:  Ling Ma; Chi-Jan Lin; Jiun-Han Chen; Chang-Phone Fung; Feng-Yee Chang; Yiu-Kay Lai; Jung-Chung Lin; L K Siu
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

6.  The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000.

Authors:  Tsai-Ling Lauderdale; L Clifford McDonald; Yih-Ru Shiau; Pei-Chen Chen; Hui-Ying Wang; Jui-Fen Lai; Monto Ho
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803
  6 in total
  23 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

2.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Kobkul Chotikanatis; Stephan A Kohlhoff; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 3.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 4.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

5.  Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.

Authors:  Zhaoxia Li; Youning Liu; Rui Wang; Aimin Li
Journal:  World J Microbiol Biotechnol       Date:  2014-08-18       Impact factor: 3.312

Review 6.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

7.  Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Authors:  Brian J Morrow; Darren Abbanat; Ellen Z Baum; Steven M Crespo-Carbone; Todd A Davies; Wenping He; Wenchi Shang; Anne Marie Queenan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

8.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

9.  Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers.

Authors:  Xiao-jie Wu; Jing Zhang; Bei-ning Guo; Ying-yuan Zhang; Ji-cheng Yu; Guo-ying Cao; Yuan-cheng Chen; De-mei Zhu; Xin-yu Ye; Ju-fang Wu; Yao-guo Shi; Li-wen Chang; Yu-ting Chang; Cheng-yuan Tsai
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.